News

The newly formed Bespoke Gene Therapy Consortium (BGTC) will team up to beat rare diseases that are currently using gene therapy.

Researchers at the University of Virginia School of Medicine have made a discovery linking lupus, a potentially debilitating autoimmune disorder, and macular degeneration, a leading cause of blindness.

Current options, challenges in developing novel therapies.

Electronic health records may be the future of practice management.

Patients’ reluctance to visit a clinic during the COVID-19 pandemic is pushing retina specialists to optimize therapy.

Under terms of the agreement, ImprimisRx to assume full responsibility for US sales and marketing activities for Dexycu.

According to the organization, the goal is to highlight and address the diverse and critical vision and eye health needs of children and to improve outcomes through advocacy, public health, education, and awareness.

Novartis has revealed the first interpretable results from year two (week 100) of the Phase III KESTREL study.

A pilot study tests the technology to obtain remote fundus imaging of patients.

Retinal and choroidal changes were observed in study.

Concise insight on education and training strategies that will optimize use of the port delivery system in retinal diseases.

Using its proprietary software, the company has been able to create models in a fraction of the time typically needed for fitting one.

AMA President Gerald E. Harmon, MD, said in a statement that President Joe Biden’s pandemic plan will make communities safer amid an evolving pandemic and confirmed cases of the Omicron variant.

According to the company, the board will support the advancement of late-stage ophthalmic assets Nyxol and APX3330.

The company’s re:Vive technology features 6 vision diagnostic exams, supported by 5 reimbursable CPT codes in 1 wearable solution.

Some studies have reported that retinal vascular permeability results in choroidal thickening, while others have reported choroidal thinning or no changes.

Chirag Jhaveri, MD, reviews the trial design and results of the LADDER and ARCHWAY studies, which tested the port delivery system in neovascular AMD.

Expert insight on the history of the port delivery system in neovascular AMD and how it has impacted patient experience and outcomes.

First annual Geographic Atrophy Awareness Week, hosted by Prevent Blindness, will be December 6-12, 2021.

Save the dates for this virtual interactive conference featuring top US ophthalmologists.

Patients can get real-time disease monitoring with self-operated device.

SD-OCT is providing reproducible, high-quality, registered images to assess the treatment response in macular disease.

The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).

Improvements are seen after gene therapy for Leber congenital amaurosis.

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

Options facilitate increased durability for patients with retinal degeneration.